在MASLD患者的塞马格卢提德:改善了生存和肝脏结果
Mohamad Suki1, Johnny Amer1, Yael Milgrom1
1Institution of Liver Diseases, Hadassah Medical Organization, Hadassah-Hebrew University, Jerusalem 91120, Israel.
Pharmaceuticals (Basel, Switzerland)
|July 30, 2025
概括
在与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者中,塞马格卢提德显著改善了生存率,并减少了心血管和肝脏疾病的进展. 这项实践研究突出了其在MASLD管理中的治疗潜力.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 构成了严重的健康负担.
- 塞马格卢提德 (SEMA) 已成为对MASLD的有前途的治疗剂.
- 现实世界的数据对于了解SEMA在MASLD的临床影响至关重要.
研究的目的:
- 评估SEMA对MASLD患者临床结果的现实影响.
- 评估SEMA对肝脏相关并发症和心血管风险的影响.
- 确定SEMA对MASLD中的代谢标记物的影响.
主要方法:
- 一个大规模的,现实世界的研究,利用TriNetX平台的非识别电子医疗记录.
- 根据34个变量,SEMA治疗的19,112名患者与19,112名非SEMA对照者的倾向性得分匹配.
- 包括通过ICD9标准诊断的成年MASLD患者,评估包括生存,代谢参数和晚期肝病进展在内的结果.
主要成果:
- 塞马治疗导致了LDL,甘油三和HbA1c水平的显著改善.
- 在SEMA治疗的患者中,低代谢标志物的发病率降低 (31.13%对34.32%).
- 与对照组相比,接受SEMA治疗的患者的存活率显著提高,心血管风险降低,肝脏疾病进展缓慢.
结论:
- 塞马格卢提德在改善MASLD患者1年生存率,心血管和肝脏相关结果方面显示出显著的好处.
- 观察到的好处很可能归因于SEMA的代谢改善和抗炎作用.
- 塞马格卢提德代表了一种潜在的有效治疗策略,用于改善MASLD的结果.
相关概念视频
01:24Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239